Interventional MR Surgery (iMRI) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Interventional MR surgery — also written as iMRI surgery or intraoperative MRI-guided neurosurgery — is a family of neurosurgical and minimally invasive brain procedures that use real-time magnetic resonance imaging to guide, monitor, or deliver treatment during the procedure itself. This distinguishes iMRI from conventional image-guided neurosurgery, which relies on pre-operative imaging that cannot account for intraoperative brain shift — the physical displacement of brain tissue that occurs after the skull is opened and cerebrospinal fluid escapes, rendering pre-operative neuronavigation progressively inaccurate by 5–10 mm over the course of a resection.

The iMRI concept encompasses three broad applications: (1) intraoperative MRI scanning performed during open tumour resection to detect and correct residual tumour before wound closure; (2) laser interstitial thermal therapy (LITT), in which MR thermometry maps laser-induced heating in real time to ablate deep-seated lesions through a burr hole; and (3) MRI-guided focused ultrasound (MRgFUS), which delivers incisionless thalamic lesioning for movement disorders using a phased-array transducer helmet.

The pivotal randomised controlled trial by Senft et al. (published in The Lancet Oncology, 2011) demonstrated that iMRI-guided resection of glioblastoma multiforme reduced residual tumour volume at final imaging: residual tumour was identified in only 3 of 24 patients in the iMRI group versus 7 of 25 in the conventional arm. Subsequent systematic reviews confirm that iMRI improves the extent of resection (EOR) by 20–30% on average across glioma grades. Greater EOR is independently associated with improved progression-free and overall survival in both high-grade and low-grade glioma.

iMRI-guided procedures address a range of intracranial and movement disorder conditions where real-time imaging feedback materially changes surgical outcomes.

• High-grade glioma (Grade III–IV, including glioblastoma multiforme, GBM): Maximum safe resection is the primary goal; iMRI identifies residual contrast-enhancing tumour not visible through the operating microscope, enabling additional resection before closure. Resection is followed by Stupp protocol (concurrent temozolomide and radiotherapy).
• Low-grade glioma (Grade II): Preserving eloquent cortex while maximising resection. iMRI combined with awake craniotomy cortical mapping is the current best-practice approach at high-volume centres.
• Pituitary adenoma and skull-base tumours: Endoscopic transsphenoidal surgery benefits from iMRI to confirm gland decompression and detect residual adenoma in the cavernous sinus.
• Brain metastases: Single or oligometastatic lesions treated with resection or LITT, particularly when located in eloquent cortex where open resection carries high morbidity.
• Drug-resistant epilepsy: MRI-guided LITT for mesial temporal lobe epilepsy (MTLE), hypothalamic hamartoma (HH), and focal cortical dysplasia. LITT achieves comparable seizure-freedom rates to open temporal lobectomy in selected patients (class II evidence).
• Essential tremor: MRgFUS unilateral Vim thalamic lesioning. FDA-approved since 2016. Immediate, durable tremor reduction in approximately 68–75% of patients at 12 months (NEJM 2016 trial, Elias et al.).
• Parkinson's disease tremor: MRgFUS unilateral thalamotomy or subthalamic ablation. FDA-approved for Parkinson's tremor since 2018.
• Radiation necrosis: LITT is emerging as a minimally invasive treatment for radiation-induced cerebral necrosis that fails steroid therapy.

Eligibility for iMRI procedures varies by the specific modality. The following general and procedure-specific criteria apply.

General requirements: Patients must be fit for the planned procedure (open craniotomy for iMRI-guided resection, or stereotactic probe placement for LITT). Standard MRI contraindications must be assessed: cardiac pacemakers, cochlear implants, metal implants, and claustrophobia. Many modern pacemakers and cochlear implants are conditionally MRI-safe; device-specific clearance from the manufacturer should be obtained before scheduling iMRI procedures. Pregnancy is a relative contraindication to iMRI procedures.

Eligibility for iMRI tumour resection: Patients with supratentorial intra-axial tumours amenable to craniotomy and gross-total or near-total resection as the surgical goal. Tumours in eloquent cortex (motor, speech, and visual areas) are ideally addressed with awake craniotomy in conjunction with iMRI. Tumours with significant mass effect, impending herniation, or causing acute neurological deterioration are managed urgently and may not wait for an iMRI-equipped theatre.

Eligibility for LITT: Lesions 0.5–3.0 cm in diameter accessible to a stereotactic probe trajectory. Deep-seated or eloquent-area lesions where open craniotomy carries high morbidity are optimal LITT candidates. LITT is preferred for radiation necrosis, small brain metastases, and mesial temporal structures in drug-resistant epilepsy.

Eligibility for MRgFUS: Patients with disabling medically refractory essential tremor or Parkinson's tremor, aged generally 22 years or above. The skull bone density ratio (SDR) is a critical technical eligibility criterion: an SDR below 0.4 on thin-slice CT limits ultrasound penetration and may result in inadequate heating at the thalamic target. Approximately 15–20% of otherwise eligible patients are excluded on this basis. Bilateral thalamic lesioning is not currently performed due to the risk of severe dysarthria and dysphagia.

The iMRI category encompasses four technically distinct modality groups, each with different infrastructure requirements, imaging quality, and clinical indications.

Low-field iMRI (0.15T, e.g., Medtronic Polestar N30): A compact movable magnet on a ceiling-mounted rail system that can be positioned over the operating table after surgical exposure, then retracted while the surgeon operates with conventional instruments. The key advantage is retrofittability to existing operating theatres at lower construction cost (approximately USD 1.5–2.5 million vs. USD 4–8 million for a dedicated high-field suite). Disadvantages include lower signal-to-noise ratio, limited sequence capability, and longer per-scan time. Adequate for identifying gross residual enhancing tumour but inferior for advanced applications such as diffusion tensor imaging (DTI) tractography.

High-field iMRI (1.5T or 3T, e.g., BrainLAB BrainSuite, IMRIS NeuroSuite, Siemens MAGNETOM Aera iMRI configuration): Dedicated suites in which the patient remains on the MRI table and is transported between the operating area and the scanner bore (or the scanner bore slides along a rail over the patient). High-field iMRI supports the full MR sequence library including DTI tractography (white matter pathway mapping), functional MRI (fMRI for pre-operative mapping during awake procedures), MR spectroscopy (tumour grading), and high-resolution contrast-enhanced T1 (residual tumour detection). The clinical yield of high-field iMRI is substantially superior to low-field systems.

Laser Interstitial Thermal Therapy (LITT): A stereotactically inserted fibre-optic laser probe (980 nm or 1064 nm diode laser) delivers thermal energy to the target lesion. MR thermometry using the proton resonance frequency (PRF) shift technique maps temperature distribution in real time, displayed as a colour overlay on anatomical MRI. Thermal damage threshold maps delineate the irreversible ablation zone, allowing the neurosurgeon to control lesion size precisely. FDA-cleared LITT systems include the Medtronic Visualase and the Monteris NeuroBlate. Typical lesion volumes are 0.3–3.0 cm³; treatment time is 15–45 minutes per target.

MRI-Guided Focused Ultrasound (MRgFUS, InSightec Exablate Neuro): A transducer helmet containing 1,024 individual ultrasound elements focuses converging beams on a thalamic or subthalamic target with sub-millimetre precision. Sub-therapeutic sonications progressively heat the target; the neurosurgeon monitors MR thermometry overlays and assesses the patient neurologically in real time before committing to the final ablative sonication. The entire procedure is performed with the patient awake in the MRI bore. No incision, no anaesthesia, no ionising radiation.

iMRI-guided procedures offer measurable clinical advantages over conventional neurosurgical approaches, supported by level I and II evidence for specific indications.

Improved extent of resection in glioma: The Senft et al. 2011 RCT (Lancet Oncology) demonstrated that iMRI-guided resection identified residual tumour requiring additional resection in 61% of procedures where the surgeon initially judged resection complete. The iMRI group achieved a greater proportion of complete resections (96% vs. 68% in the conventional arm). Extended follow-up data from multiple European and US centres confirm a 20–30% improvement in volumetric EOR with iMRI guidance.

Real-time correction of brain shift: Intraoperative brain shift of 5–15 mm renders conventional pre-operative neuronavigation increasingly inaccurate as surgery progresses. iMRI provides current anatomical ground truth, restoring navigation accuracy and reducing the risk of inadvertent damage to eloquent structures.

Reduction in repeat surgery: Higher EOR at the index procedure reduces the rate of early re-operation for residual tumour, sparing the patient a second craniotomy and its associated morbidity.

LITT clinical advantages: LITT provides access to deep-seated, eloquent, or previously irradiated lesions that carry high open-surgical morbidity. Hospital stay is typically 1–2 days versus 4–7 days for open craniotomy. Progression-free survival data for LITT-treated radiation necrosis and recurrent GBM are comparable to open re-resection in retrospective series.

MRgFUS advantages: Immediate tremor reduction without surgical incision, general anaesthesia, or implanted hardware. The NEJM 2016 placebo-controlled trial (Elias et al.) demonstrated a mean improvement in the Clinical Rating Scale for Tremor (CRST) of 47% vs. no improvement in the sham arm at 3 months. Benefits are durable at 5-year follow-up in most responders. For patients unsuitable for deep brain stimulation (DBS) surgery, MRgFUS represents a compelling alternative.

iMRI procedures, while offering distinct advantages, carry specific risks related to the technology, surgical environment, and patient factors.

Operational risks in the iMRI OR: The iMRI environment requires MRI-compatible surgical instruments, anaesthesia equipment (non-ferromagnetic), and monitoring systems. Extended procedure times (30–60 minutes additional for scan transfer and image review) increase anaesthesia duration, blood loss, and infection risk. Ferromagnetic projectile hazards require rigorous protocol adherence. Staff training and familiarity with the iMRI workflow are critical safety determinants.

LITT-specific risks: Probe track haemorrhage (approximately 1–2% of procedures); thermal injury to adjacent neural structures if real-time thermometry margins are not respected; cerebral oedema in the days following ablation (managed with corticosteroids); and catheter displacement prior to laser activation. The heat-sink effect from adjacent cerebral blood vessels can limit the ablation zone in vascular tumour regions.

MRgFUS risks: Skull bone density ratio below 0.4 precludes adequate energy focusing and is a contraindication. Procedural adverse effects include headache (common, transient), paraesthesia, gait imbalance, and dizziness during sonication — most resolving within 24–72 hours. Persistent side effects (unilateral sensory deficits, dysarthria) occur in 3–10% of patients; most are mild and transient. Severe speech or swallowing impairment occurs in less than 1% with experienced operators using standardised targeting protocols. Bilateral procedures are not currently performed.

General iMRI limitations: High-field iMRI suites are available only at major academic or tertiary referral centres, limiting accessibility. The infrastructure investment is substantial. Not all neurosurgeons are trained in iMRI workflows. Patient claustrophobia may limit tolerance of the MRI environment during or between surgical steps.

Post-procedure monitoring and follow-up differ across the three iMRI modality groups and must be tailored to the specific intervention performed.

After iMRI-guided tumour resection: Standard post-craniotomy monitoring in a neurosurgical high-dependency unit (HDU) for 24–48 hours. Post-operative MRI (contrast-enhanced T1 and FLAIR) is performed within 24–72 hours to document the extent of resection and establish a new baseline. Neuropathology results from intraoperative frozen section and definitive histology guide adjuvant therapy decisions. For GBM, the Stupp protocol (concurrent radiotherapy 60 Gy in 30 fractions plus temozolomide, followed by 6 cycles adjuvant temozolomide) is initiated within 4–6 weeks of surgery. Neuropsychological assessment and physiotherapy input are arranged as indicated by the patient's functional profile.

After LITT: Patients are typically observed for 24–48 hours post-procedure. Post-LITT MRI at 24–48 hours confirms the treatment zone (central non-enhancing ablation zone surrounded by a ring of perilesional oedema). Corticosteroids (dexamethasone) are given for 7–14 days to manage peri-ablation oedema. Seizure prophylaxis is continued for patients with epilepsy-related LITT. Clinical neurological assessment at 2 weeks, 6 weeks, and 3 months post-procedure; imaging at 6–12 weeks to assess treatment response.

After MRgFUS: Patients are discharged the same day or after one overnight observation in most centres. Clinical neurological assessment of tremor control, speech, and gait is performed immediately post-procedure in the MRI suite, and again at 1 week, 1 month, 3 months, and 12 months. Audiometric testing is performed at 1 month (cochlear proximity effect). The ablation lesion is visible on T2-weighted MRI as a 3–5 mm T2-bright area in the Vim thalamus; no further treatment or medication management is typically required in responders.

Long-term oncological surveillance: MRI-based imaging follow-up for brain tumour patients is performed per national and institutional oncology protocols — typically every 2–3 months for GBM patients on temozolomide, and every 6 months for low-grade glioma in remission. Pseudoprogression (treatment-related inflammatory change mimicking tumour progression) on MRI at 2–3 months must be distinguished from true progression, ideally using MR perfusion and spectroscopy.

iMRI surgery is a high-cost subspecialty service due to the infrastructure investment, specialised OR equipment, and the concentration of expertise in tertiary academic centres. Understanding the cost landscape helps patients plan appropriately and identify medical tourism options where iMRI services are available at significantly lower cost.

Infrastructure and institutional costs: A low-field iMRI OR installation costs approximately USD 1.5–2.5 million; a high-field dedicated iMRI suite (1.5T or 3T) ranges from USD 3–8 million in capital expenditure. These costs are reflected in higher facility charges. In the US, iMRI-guided craniotomy adds approximately USD 5,000–15,000 to the base cost of a conventional craniotomy.

Procedure costs in the US: iMRI craniotomy for glioma: USD 50,000–120,000 all-inclusive. LITT: USD 35,000–65,000. MRgFUS: USD 25,000–40,000 (variable by centre and insurance coverage; FDA approval since 2016 means many US insurers now cover MRgFUS for essential tremor).

Medical tourism access: iMRI capabilities at internationally accredited centres are available in several medical tourism destinations at significantly reduced cost. Apollo Hospitals (India) and several South Korean and German academic centres offer iMRI-guided tumour surgery and LITT at 40–65% of US prices. MRgFUS is available through National Health Service programmes in the UK and through academic centres in Israel (the original developer country), South Korea, Germany, and Canada, often with public funding support.

Insurance coverage: In most countries, iMRI tumour surgery and LITT for brain malignancy are covered by public and private insurance when performed at accredited neurosurgical centres. MRgFUS for essential tremor gained NHS England funding in 2021. Coverage for MRgFUS in Parkinson's disease is expanding as post-market surveillance data mature.

iMRI-guided procedures represent the current technological frontier but are not the only effective options. Understanding alternatives helps patients and clinicians make evidence-based, patient-centred decisions.

Conventional microsurgical craniotomy with neuronavigation: The standard of care at most neurosurgical centres worldwide. Neuronavigation systems (BrainLAB Kick, Medtronic StealthStation) use pre-operative MRI data to guide resection. As noted, navigational accuracy degrades with brain shift during surgery. For experienced high-volume neurosurgeons, outcomes are excellent for accessible superficial tumours; the principal limitation is the inability to detect residual tumour in real time.

Awake craniotomy with cortical mapping: The gold standard for tumours in eloquent cortex. The patient is kept awake during resection to allow continuous neurological monitoring (speech, motor function). Combined with neuronavigation and intraoperative electrocorticography (ECoG), awake craniotomy achieves high EOR rates with low functional morbidity and is complementary to — rather than competing with — iMRI guidance.

Stereotactic radiosurgery (SRS): Gamma Knife (Elekta), CyberKnife (Accuray), and linear accelerator-based SRS deliver high-dose, single-fraction or hypofractionated radiation to intracranial lesions with sub-millimetre precision. Standard of care for brain metastases (<4 lesions, <4 cm each), acoustic neuromas, and AVM. Not a substitute for resection in large, mass-effect-producing tumours requiring immediate cytoreduction.

Deep brain stimulation (DBS) for movement disorders: DBS involves surgical implantation of electrodes in the subthalamic nucleus (STN) or globus pallidus internus (GPi) connected to an implanted pulse generator. DBS is reversible, adjustable, and bilateral — advantages over MRgFUS ablation. However, DBS requires hardware implantation, ongoing programming, and battery replacement every 3–5 years. For patients who are poor surgical candidates or prefer a non-implant approach, MRgFUS is preferred.

Conventional medical management: Temozolomide-based chemotherapy and anti-epileptic medication remain foundational treatments for glioma and epilepsy respectively. Medical management is the baseline from which surgical or ablative interventions are considered when drug resistance develops or tumour progression occurs.